A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer

Conditions:   Metastatic Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Pyrotinib;   Drug: SHR6390;   Drug: Letrozole;   Drug: Capecitabine Sponsors:   Jinming Yu;   Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials